These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16023993)

  • 1. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
    Corbin JD; Beasley A; Blount MA; Francis SH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
    Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
    Sung BJ; Hwang KY; Jeon YH; Lee JI; Heo YS; Kim JH; Moon J; Yoon JM; Hyun YL; Kim E; Eum SJ; Park SY; Lee JO; Lee TG; Ro S; Cho JM
    Nature; 2003 Sep; 425(6953):98-102. PubMed ID: 12955149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.
    Corbin J; Francis S; Zoraghi R
    Int J Impot Res; 2006; 18(3):251-7. PubMed ID: 16281046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
    Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
    Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
    Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
    Corbin JD; Beasley A; Blount MA; Francis SH
    Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
    Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
    Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
    Corbin JD; Francis SH
    Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
    Bischoff E
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S11-4. PubMed ID: 15224129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
    Filippi S; Morelli A; Sandner P; Fibbi B; Mancina R; Marini M; Gacci M; Vignozzi L; Vannelli GB; Carini M; Forti G; Maggi M
    Endocrinology; 2007 Mar; 148(3):1019-29. PubMed ID: 17138653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.
    Zhang XH; Morelli A; Luconi M; Vignozzi L; Filippi S; Marini M; Vannelli GB; Mancina R; Forti G; Maggi M
    Eur Urol; 2005 Mar; 47(3):409-16; discussion 416. PubMed ID: 15716209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
    Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
    Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
    Zhang L; Zhang Z; Zhang RL; Cui Y; LaPointe MC; Silver B; Chopp M
    Brain Res; 2006 Nov; 1118(1):192-8. PubMed ID: 16959227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
    Hemnes AR; Champion HC
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):293-300. PubMed ID: 16716091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.
    Shimizu-Albergine M; Rybalkin SD; Rybalkina IG; Feil R; Wolfsgruber W; Hofmann F; Beavo JA
    J Neurosci; 2003 Jul; 23(16):6452-9. PubMed ID: 12878685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gamma-subunit of the rod photoreceptor cGMP-binding cGMP-specific PDE is expressed in mouse lung.
    Tate RJ; Lochhead A; Brzeski H; Arshavsky V; Pyne NJ
    Cell Biochem Biophys; 1998; 29(1-2):133-44. PubMed ID: 9631242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
    Nagendran J; Archer SL; Soliman D; Gurtu V; Moudgil R; Haromy A; St Aubin C; Webster L; Rebeyka IM; Ross DB; Light PE; Dyck JR; Michelakis ED
    Circulation; 2007 Jul; 116(3):238-48. PubMed ID: 17606845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.